Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men

European Journal of Endocrinology

Volumn 164, Issue 6, 2011, Pages 1013-1018

  Möhlig, Matthias ^a,b   Arafat, Ayman M ^a,b   Osterhoff, Martin A ^b   Isken, Frank ^a,b   Weickert, Martin O ^a,c,d   Spranger, Joachim ^a,b   Pfeiffer, Andreas F H ^a,b   Schöfl, Christof ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; TESTOSTERONE; ADENOSINE; CYTIDINE; GLUCOSE; GUANOSINE;

ADULT; AGE; ARTICLE; BODY MASS; CAG REPEAT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GLUCOSE TOLERANCE; HETEROZYGOTE; HORMONE ACTION; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HOMEOSTASIS; INSULIN RESISTANCE; PREDICTION;

BLOOD GLUCOSE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; GONADAL STEROID HORMONES; HETEROZYGOTE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; REGRESSION ANALYSIS; REPETITIVE SEQUENCES, NUCLEIC ACID; TESTOSTERONE;

EID: 79957747164     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-1022     Document Type: Article

References (43)

1. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Annals of Internal Medicine 1992 117 807-811.
2. Svartberg J, von Muhlen D, Sundsfjord J & Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso study. European Journal of Epidemiology 2004 19 657-663. (doi:10.1023/B:EJEP. 0000036809.30558.8f)
3. Haring R, Völzke H, Felix SB, Schipf S, Dörr M, Rosskopf D, Nauck M, Schöfl C & Wallaschofski H. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009 58 2027-2031. (doi:10.2337/db09-0031)
4. Yeap BB, Chubb SA, Hyde Z, Jamrozik K, Hankey GJ, Flicker L & Norman PE. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health in Men Study. European Journal of Endocrinology 2009 161 591-598. (doi:10.1530/EJE-09-0348)
5. Li C, Ford ES, Li B, Giles WH & Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 2010 33 1618-1624. (doi:10.2337/dc09-1788)
6. Racette SB, Evans EM, Weiss EP, Hagberg JM & Holloszy JO. Abdominal adiposity is a stronger predictor of insulin resistance than fitness among 50-95 year olds. Diabetes Care 2006 29 673-678. (doi:10.2337/diacare.29.03.06.dc05- 1605)
7. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA & Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992 41 715-722. (doi:10.2337/diabetes.41.6.715)
8. Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi GM & Dandona P. The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 2007 30 1860-1861. (doi:10.2337/dc07- 0337)
9. Kapoor D, Goodwin E, Channer KS & Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006 154 899-906. (doi:10.1530/eje.1.02166)
10. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ III, Smith GE, Khosla S & Jensen MD. DHEA in elderly women and DHEA or testosterone in elderly men. New England Journal of Medicine 2006 355 1647-1659. (doi:10.1056/NEJMoa054629)
11. Nowicki M, Bryc W & Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. Journal of Endocrinological Investigation 2001 24 31-36. (Pubitemid 32166326)
12. Smith MR, Lee H & Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism 2006 91 1305-1308. (doi:10.1210/jc.2005-2507)
13. Keating NL, O'Malley AJ, Freedland SJ & Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of National Cancer Institute 2010 102 39-46. (doi:10.1093/jnci/djp404)
14. Saad F, Gooren L, Haider A & Yassin A. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia 2008 40 44-48. (doi:10.1111/j.1439-0272.2008.00807.x)
15. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE & van der Schouw YT. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Journal of the American Medical Association 2008 299 39-52. (doi:10.1001/jama.2007.51)
16. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD & Bhasin S. Adverse events associated with testosterone administration. New England Journal of Medicine 2010 363 109-122. (doi:10.1056/NEJMoa1000485)
17. Chamberlain NL, Driver ED & Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research 1994 22 3181-3186. (doi:10.1093/nar/22.15.3181)
18. Beilin J, Ball EM, Favaloro JM & Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. Journal of Molecular Endocrinology 2000 25 85-96. (doi:10.1677/jme.0.0250085)
19. Zitzmann M & Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2007 92 3844-3853. (doi:10.1210/jc.2007-0620)
20. Huhtaniemi IT, Pye SR, Limer KL, Thomson W, O'Neill TW, Platt H, Payne D, John SL, Jiang M, Boonen S, Borghs H, Vanderschueren D, Adams JE, Ward KA, Bartfai G, Casanueva F, Finn JD, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ & Wu FC. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. Journal of Clinical Endocrinology and Metabolism 2009 94 277-284. (doi:10.1210/jc.2008-0848)
21. Vermeersch H, T'Sjoen G, Kaufman JM, Vincke J & Van Houtte M. Testosterone, androgen receptor gene CAG repeat length, mood and behaviour in adolescent males. European Journal of Endocrinology 2010 163 319-328. (doi:10.1530/EJE-10-0090)
22. Zitzmann M, Gromoll J, von Eckardstein A & Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 2003 46 31-39. (doi:10.1007/s00125-002-0980-9)
23. Skjaerpe PA, Giwercman YL, Giwercman A & Svartberg J. Androgen receptor gene polymorphism and the metabolic syndrome in 60-80 years old Norwegian men. International Journal of Andrology 2010 33 500-506. (doi:10.1111/j.1365-2605.2008.00942.x)
24. Möhlig M, Jürgens A, Spranger J, Hoffmann K, Weickert MO, Schlösser HW, Schill T, Brabant G, Schüring A, Pfeiffer AF, Gromoll J & Schöfl C. The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. European Journal of Endocrinology 2006 155 127-130. (doi:10.1530/eje.1.02195)
25. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Möhlig M, Pfeiffer AF, Spranger J, Thamer C, Häring HU, Fritsche A & Joost HG. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 2007 30 510-515. (doi:10.2337/dc06-2089)
26. Ruhla S, Weickert MO, Arafat AM, Osterhoff M, Isken F, Spranger J, Schöfl C, Pfeiffer AF & Möhlig M. A high normal TSH is associated with the metabolic syndrome. Clinical Endocrinology 2010 72 696-701. (doi:10.1111/j.1365-2265.2009.03698.x)
27. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. In: Report of a WHO Consultation, Part 1. WHO, 1999.
28. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672. (doi:10.1210/jc.84.10.3666)
29. Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G & Schöfl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. European Journal of Endocrinology 2004 150 525-532. (doi:10.1530/eje.0.1500525)
30. Levy JC, Matthews DR & Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998 21 2191-2192. (doi:10.2337/diacare.21.12.2191)
31. Kahn R, Buse J, Ferrannini E & Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005 48 1684-1699. (doi:10.1007/s00125-005-1876-2)
32. Vikan T, Schirmer H, Njolstad I & Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. European Journal of Endocrinology 2010 162 747-754. (doi:10.1530/EJE-09-0943)
33. Nenonen H, Bjork C, Skjaerpe PA, Giwercman A, Rylander L, Svartberg J & Giwercman YL. CAG repeat number is not inversely associated with androgen receptor activity in vitro. Molecular Human Reproduction 2010 16 153-157. (doi:10.1093/molehr/gap097)
34. Shimbo M, Suzuki H, Kamiya N, Imamoto T, Komiya A, Ueda T, Watanabe M, Shiraishi T & Ichikawa T. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. European Urology 2005 47 557-563. (doi:10.1016/j.eururo.2004.10.016)
35. Stanworth RD, Kapoor D, Channer KS & Jones TH. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology 2008 159 739-746. (doi:10.1530/EJE-08-0266)
36. Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A & Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. Journal of Clinical Endocrinology and Metabolism 2001 86 4867-4873. (doi:10.1210/jc.86.10.4867)
37. Despres JP & Lemieux I. Abdominal obesity andmetabolic syndrome. Nature 2006 444 881-887. (doi:10.1038/nature05488)
38. Travison TG, Shackelton R, Araujo AB, Morley JE, Williams RE, Clark RV & McKinlay JB. Frailty, serum androgens, and the CAG repeat polymorphism: results from the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism 2010 95 2746-2754. (doi:10.1210/jc.2009-0919)
39. Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM & Figg WD. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate 2010 70 584-590. (doi:10.1002/pros.21092)
40. Guadalupe-Grau A, Rodriguez-Gonzalez FG, Ponce-Gonzalez JG, Dorado C, Olmedillas H, Fuentes T, Perez-Gomez J, Sanchis-Moysi J, Diaz-Chico BN & Calbet JA. Bone mass and the CAG and GGN androgen receptor polymorphisms in young men. PLoS ONE 2010 5 e11529. (doi:10.1371/journal.pone.0011529)
41. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/diacare.27.6.1487)
42. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM & Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine 2009 361 1152-1163. (doi:10.1056/NEJMoa0804381)
43. Spratt DI, Morton JR, Kramer RS, Mayo SW, Longcope C & Vary CP. Increases in serum estrogen levels during major illness are caused by increased peripheral aromatization. American Journal of Physiology, Endocrinology and Metabolism 2006 291 E631-E638. (doi:10.1152/ajpendo.00467.2005)